Ovarian cancer has the highest mortality rate in female malignant tumors of reproduc-tive system,with high recurrence rate and secondary resistance to platinum-containing chemotherapy.In recent years,adoptive cell immunotherapy(ACT),as an emerging immunotherapeutic strategy,shows great potential in the treatment of ovarian cancer.Although the immunosuppressive microenvironment and limited target selection are still the main challenges facing the current ACT treatment for ovarian cancer,it is still expected that the efficacy of ACT in ovarian cancer patients can be further improved by optimizing the cell production techniques and combining multiple thera-peutic approaches.This paper aims to provide a reference for the development of innovative thera-pies for ovarian cancer by reviewing the latest research progress on the mechanism and application of ACT therapy in ovarian cancer.

Ovarian cancer has the highest mortality rate in female malignant tumors of reproduc-tive system,with high recurrence rate and secondary resistance to platinum-containing chemotherapy.In recent years,adoptive cell immunotherapy(ACT),as an emerging immunotherapeutic strategy,shows great potential in the treatment of ovarian cancer.Although the immunosuppressive microenvironment and limited target selection are still the main challenges facing the current ACT treatment for ovarian cancer,it is still expected that the efficacy of ACT in ovarian cancer patients can be further improved by optimizing the cell production techniques and combining multiple thera-peutic approaches.This paper aims to provide a reference for the development of innovative thera-pies for ovarian cancer by reviewing the latest research progress on the mechanism and application of ACT therapy in ovarian cancer.

OBJECTIVETo investigate the anti-human CEM lymphoma cell activities induced by TCR idiotypic DNA vaccine containing different antigen determinants in BALB/c mice.

METHODSThe specific rearranged gene fragment encoding TCRVbeta region of CEM cell line was obtained by RT-PCR technique. The PCR product was cloned into eukaryocytic expression vector pcDNA3, which was used as DNA vaccine and template for PCR amplifying different antigen determinant. Gene fragments encoding different antigen determinant were amplified and cloned into pcDNA3, separately. The experimental mice were immunized by intramuscular injection of the DNA vaccines. The specific anti-idiotype antibodies were detected by indirect immunofluorescence assay.

RESULTSTCRbetaV of CEM cell line contains five antigen determinants. Specific anti-idiotype antibody was detected in all of the six mice immunized with DNA vaccine containing all the five determinants (the highest titer was 1:480). Although the antibody could also be detected in four of the six mice immunized with DNA vaccine containing four of the five antigen determinants, the antibody titer was lower (the highest titer was 1:80). DNA vaccine containing two of the five determinants could not induce the specific antibody.

CONCLUSIONThe idiotypic DNA vaccine containing the whole TCRbetaV five antigen determinants could induce the specific anti-lymphoma idiotypic antibody in BALB/c mice.

Amino Acid Sequence ; Animals ; Antibodies, Anti-Idiotypic ; blood ; immunology ; Base Sequence ; Complementarity Determining Regions ; genetics ; immunology ; Epitopes ; genetics ; immunology ; HL-60 Cells ; Humans ; Lymphoma ; immunology ; Mice ; Mice, Inbred BALB C ; Molecular Sequence Data ; Receptors, Antigen, T-Cell, alpha-beta ; genetics ; immunology ; Sequence Analysis, DNA ; Tumor Cells, Cultured ; Vaccines, DNA ; genetics ; immunology